These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37716956)

  • 1. Periostin drives extracellular matrix degradation, stemness, and chemoresistance by activating the MAPK/ERK signaling pathway in triple-negative breast cancer cells.
    Wu J; Li J; Xu H; Qiu N; Huang X; Li H
    Lipids Health Dis; 2023 Sep; 22(1):153. PubMed ID: 37716956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6/STAT3/pentraxin 3/matrix metalloproteinase 7 axis.
    Xie H; Ruan G; Wei L; Zhang H; Shi J; Lin S; Liu C; Liu X; Zheng X; Chen Y; Deng L; Shi H
    Int Immunopharmacol; 2024 Jul; 136():112332. PubMed ID: 38805776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.
    Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C
    Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.
    Li J; Gao R; Zhang J
    Clin Breast Cancer; 2023 Feb; 23(2):162-175. PubMed ID: 36528490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
    Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
    Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2.
    Wu A; Wang X; Zhang F; Yang X; Quan Y; Dong J; Lai Y; Yang D; Sun J; Wang M
    Mol Carcinog; 2024 Mar; 63(3):417-429. PubMed ID: 37983722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
    Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
    Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
    Lyes MA; Payne S; Ferrell P; Pizzo SV; Hollenbeck ST; Bachelder RE
    Breast Cancer Res Treat; 2019 Apr; 174(2):413-422. PubMed ID: 30594967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
    Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
    Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling.
    Huang S; Huang P; Wu H; Wang S; Liu G
    Folia Histochem Cytobiol; 2021; 59(4):291-301. PubMed ID: 34970732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
    He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
    Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.